Discover how CorMedix is advancing its initiatives and adapting to reimbursement changes in specialty pharmaceuticals at the Citizens Life Sciences Conference.

New Medicare Part D rules in 2025 cap oral cancer drug costs at $2,000 annually and introduce a voluntary monthly payment plan to improve affordability for patients.